Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations say.

Canada’s panel of vaccine advisers has strongly recommended the new vaccines targeting the KP.2 strain, part of the Omicron lineage, for the previously vaccinated or unvaccinated at increased risk of ...

Nova Scotia’s Progressive Conservatives say that if re-elected Nov. 26 they will introduce a universal shingles vaccine program for people 65 and older.

The global health agency said on Wednesday the newly allocated vaccines will go to the Central African Republic, Ivory Coast, the Democratic Republic of Congo, Kenya, Liberia, Nigeria, Rwanda, South A ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...